13F Filings History of BRAIDWELL LP
- Latest 13F filing
- Q1 2026 - 15 May 2026
- Latest reported 13F value
- $2,997,744,331
- Form 13F summary
-
- BRAIDWELL LP Form 13F history summarizes parsed U.S.-listed equity disclosures for this manager.
- Form 13F is generally due within 45 days after each calendar quarter ends.
- BRAIDWELL LP reported 88 equity holdings with a total reported market value of $2,997,744,331 for Q1 2026. Top reported holdings included CAI, GUARDANT HEALTH INC, REPLIGEN CORP, NEOGENOMICS INC, and NBIX.
- Largest 13F holdings
-
CAI GUARDANT HEALTH INC REPLIGEN CORP NEOGENOMICS INC NBIX GKOS CNTA XENE DNTH EWTX IRTC NUVL
+8 more
KOD CGON ALPHATEC HLDGS INC ARGX HNGE ACAD GLUE KRYS - Manager signature
- Ken Joseph - Chief Compliance Officer
- Manager location
- Stamford, CT
13F snapshot
Latest parsed holdings, value, and filing-period context.
2 signals
Manager
Names, identifiers, and filing context for this profile.
2 identity fields
Follow Filing Activity
Follow BRAIDWELL LP with Pro and return when a new 13F portfolio filing changes the record on this page.
Pro alert delivery is coming soon and remains tied to source-backed filing changes rather than inferred market advice.
Holdings Value
Form 13F evidence
Quarterly portfolio filings
SEC-reported 13F quarters for this filer, ordered by the latest accepted filing.
Latest quarter
Q1 2026
Latest value
$2,997,744,331
Quarter delta
-$129,255,409
Accepted
15 May 2026, 16:08
Rows shown
1-14 of 14
| Quarter | Holdings | SEC-reported value | Bought | Sold | Net | Top Holdings | Form Type | Accepted by SEC |
|---|---|---|---|---|---|---|---|---|
| Q1 2026 | 88 | $2,997,744,331 | +$753,141,357 | -$862,875,282 | -$109,733,925 | CAI, GUARDANT HEALTH INC, REPLIGEN CORP, NEOGENOMICS INC, NBIX | 13F-HR | 15 May 2026, 16:08 |
| Q4 2025 | 73 | $3,126,999,740 | +$722,490,100 | -$1,480,181,233 | -$757,691,133 | CAI, GUARDANT HEALTH INC, EWTX, REPLIGEN CORP, NBIX | 13F-HR | 17 Feb 2026, 17:12 |
| Q3 2025 | 73 | $3,370,348,920 | +$737,465,023 | -$575,050,783 | +$162,414,240 | GUARDANT HEALTH INC, CAI, NOVOCURE LTD, XENE, CGON | 13F-HR | 14 Nov 2025, 16:07 |
| Q2 2025 | 55 | $2,923,924,032 | +$499,741,109 | -$570,956,679 | -$71,215,570 | GUARDANT HEALTH INC, CAI, NBIX, NOVOCURE LTD, XENE | 13F-HR | 14 Aug 2025, 16:34 |
| Q1 2025 | 64 | $2,844,802,567 | +$846,348,550 | -$1,118,782,305 | -$272,433,755 | GUARDANT HEALTH INC, NOVOCURE LTD, NBIX, LEGN, REPLIGEN CORP | 13F-HR | 15 May 2025, 16:34 |
| Q4 2024 | 73 | $3,372,652,431 | +$584,985,822 | -$597,705,270 | -$12,719,448 | GUARDANT HEALTH INC, BRIDGEBIO PHARMA INC, NOVOCURE LTD, NBIX, REPLIGEN CORP | 13F-HR | 14 Feb 2025, 16:18 |
| Q3 2024 | 81 | $3,527,985,574 | +$699,942,636 | -$551,185,675 | +$148,756,961 | GUARDANT HEALTH INC, BRIDGEBIO PHARMA INC, NOVOCURE LTD, CGON, NUVASIVE INC | 13F-HR | 14 Nov 2024, 16:22 |
| Q2 2024 | 75 | $3,187,767,909 | +$925,413,405 | -$688,113,088 | +$237,300,317 | GUARDANT HEALTH INC, BRIDGEBIO PHARMA INC, NOVOCURE LTD, NUVASIVE INC, NBIX | 13F-HR | 14 Aug 2024, 16:29 |
| Q1 2024 | 70 | $3,102,773,641 | +$917,098,241 | -$612,267,221 | +$304,831,020 | GUARDANT HEALTH INC, BRIDGEBIO PHARMA INC, EXACT SCIENCES CORP, NOVOCURE LTD, APGE | 13F-HR | 15 May 2024, 16:26 |
| Q4 2023 | 72 | $2,722,670,757 | +$374,961,295 | -$1,014,613,338 | -$639,652,043 | GUARDANT HEALTH INC, BRIDGEBIO PHARMA INC, ASCENDIS PHARMA A/S, EXACT SCIENCES CORP, NOVOCURE LTD | 13F-HR | 14 Feb 2024, 16:37 |
| Q3 2023 | 85 | $3,164,360,709 | +$710,756,067 | -$423,382,214 | +$287,373,853 | GUARDANT HEALTH INC, NOVOCURE LTD, ASCENDIS PHARMA A/S, EXACT SCIENCES CORP, NANOSTRING TECHNOLOGIES INC | 13F-HR | 14 Nov 2023, 16:36 |
| Q2 2023 | 81 | $3,060,428,640 | +$589,173,408 | -$680,885,126 | -$91,711,718 | GUARDANT HEALTH INC, EXACT SCIENCES CORP, NOVOCURE LTD, NANOSTRING TECHNOLOGIES INC, ASCENDIS PHARMA A/S | 13F-HR | 14 Aug 2023, 16:29 |
| Q1 2023 | 81 | $2,924,706,963 | +$463,204,594 | -$495,570,711 | -$32,366,117 | GUARDANT HEALTH INC, EXACT SCIENCES CORP, NANOSTRING TECHNOLOGIES INC, NOVOCURE LTD, ALPHATEC HLDGS INC | 13F-HR | 15 May 2023, 17:18 |
| Q4 2022 | 88 | $2,946,459,579 | $0 | $0 | $0 | GUARDANT HEALTH INC, NANOSTRING TECHNOLOGIES INC, NOVOCURE LTD, EXACT SCIENCES CORP, ALPHATEC HLDGS INC | 13F-HR | 14 Feb 2023, 16:27 |